Is growth hormone deficiency contributing to heart failure in patients with β-thalassemia major?

European Journal of Endocrinology

Volumn 151, Issue 2, 2004, Pages 161-166

  Erfurth, Eva Marie ^a   Holmer, Helene ^b   Nilsson, Per Gunnar ^a   Kornhall, Björn ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; CANRENOIC ACID; CARVEDILOL; DEFEROXAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; GROWTH HORMONE; HUMAN GROWTH HORMONE; IRON; LEVOTHYROXINE; METOLAZONE; SPIRONOLACTONE; TORASEMIDE;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CASE REPORT; DISEASE CLASSIFICATION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; GROWTH HORMONE DEFICIENCY; HEART FAILURE; HEART FUNCTION; HEART MUSCLE BIOPSY; HOSPITAL ADMISSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LOW DRUG DOSE; MYOCARDITIS; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; BETA-THALASSEMIA; CARDIOTONIC AGENTS; DEFEROXAMINE; FEMALE; HEART FAILURE, CONGESTIVE; HUMAN GROWTH HORMONE; HUMANS; IRON CHELATING AGENTS;

EID: 4444250790     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1510161     Document Type: Article

References (27)

1. Hershko C & Rachmilewitz EA. Mechanism of desferrioxamine-induced iron excretion in thalassaemia. British Journal of Haematology 1979 42 125-132.
2. Hershko C. Iron chelators for thalassaemia. British Journal of Haematology 1998 101 399-406.
3. Link G, Pinson A & Hershko C. The ability of orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxmanine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood 1994 83 2692-2697.
4. Link G, Pinson A & Hershko C. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. Journal of Laboratory and Clinical Medicine 1993 121 127-134.
5. Link G, Tirosh R, Pinson A & Hershko C. Role of iron in the potentiation of anthracycline toxicity: identification of heart cell mitochondria as the site of iron-anthracycline interaction. Journal of Laboratory and Clinical Medicine 1996 127 272-278.
6. De Sanctis V, Pintor C & Aliquo MC. Prevalence of endocrine complications in patients with β-thalassemia major: an Italian multicenter study. In Advances in Pediatric Endocrinology, pp 127-133. Eds C Pinctor, E Muller, S Loche & MI New. Berlin: Springer, 1992.
7. Link G, Athias P, Grynberg A & Pinson A. Effect of iron loading on transmembrane potential, contraction and automaticity of rat ventricular muscle cells in culture. Journal of Laboratory and Clinical Medicine 1989 113 103-111.
8. Olivieri NF, Nathan DG, Macmillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G & Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. New England Journal of Medicine 1994 331 574-578.
9. Wonke B. Clinical management of beta-thalassemia major. Seminars in Hematology 2001 38 350-359.
10. Kremastinos DT, Flevari P, Spyropoulou M, Vrettou H, Tsiapras D & Stavropoulos-Giokas CG. Association of heart failure in homozygous β-thalassemia with the major histocompatibility complex. Circulation 1999 100 2074-2078.
11. Cuneo RC, Wilshurt P, Lowy C, McGauley G & Sönksen PH. Heart failure responding to growth hormone. Lancet 1989 15 838-839.
12. Fruscat A, Perrone GA, Gentiloni N & Russo MA. Reversible dilated cardiomyopathy due to growth hormone deficiency. American Journal of Clinical Pathology 1992 97 503-511.
13. Lombardo T, Tamburino C, Bartolino G, Morrone ML, Frontini V, Italia F, Cordaro S, Privitera A & Calvi V. Cardiac iron overload in thalassemia patients: an endomyocardial biopsy study. Annals of Hematology 1995 71 135-141.
14. Marcus RE, Davies SC, Bantock HM, Underwood SR, Walton S & Huehns ER. Desferoxamine to improve cardiac function in iron-overloaded patients with thalassemia major. Lancet 1984 18 392-393.
15. Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini D, Marciano-Mone C, Sacca L & Bellastella A. Body composition, bone metabolism, and heart structure and function in growth hormone (GH) deficient adults before and after GH replacement therapy at low doses. Journal of Clinical Endocrinology and Metabolism 1993 77 1671-1676.
16. Merola B, Cittadini A, Colao A, Longobardi S, Fazio S, Sabatini D, Sacca L & Lombardi G. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1993 77 1658-1661.
17. Cittadini A, Cuocolo A, Merola B, Fazio S, Sabatin D, Nicolai E, Colao A, Longobardi S, Lombardi G & Sacca L. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. American Journal of Physiology 1994 267 219-225.
18. Maison P & Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 2003 108 2648-2652.
19. Link K, Bülow B, Eskilsson J, Westman K, Salmonson EC & Erfurth EM. Low individualized growth hormone (GH) dose increased renal and cardiac growth in childhood onset GH deficiency. Clinical Endocrinology 2001 55 741-748.
20. Ross J & Ryoke T. Effect of growth hormone and insulin-like growth factor I in experimental heart failure. Growth Hormone and IGF Research 1998 8 159-161.
21. Isgaard J, Tivesten Å, Friberg P & Bengtsson BÅ. The role of the GH/IGF-I axis for cardiac function and structure. Hormone and Metabolic Research 1999 31 50-54.
22. Volterrani M, Desenzani P, Lorusso R, D'Aloia A, Manelli F & Giustina A. Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 1997 349 1067-1068.
23. O'Driscoll JG, Green DJ, Ireland M, Kerr D & Larbalestier RI. Treatment of end-stage cardiac failure with growth hormone. Lancet 1997 349 1068.
24. Lissett CA, Murray RD & Shalet SM. Timing of onset of growth hormone deficiency is a major influence on insulin-like growth factor I status in adult life. Clinical Endocrinology 2002 118 58-66.
25. Growth Hormone Research Society (GRS). Consensus guidelines for the diagnosis and treatment of adults with GH deficiency: summary statement of the GRS workshop on adult GHD. Journal of Clinical Endocrinology and Metabolism 1998 34 379-381.
26. Fazio S, Biondi B, Sabatini D, Cuocolo A, Tommaselli P, Lombardi G & Sacca L. Long-term GH deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy. Journal of Clinical Endocrinology and Metabolism 1996 81 887-890.
27. Hoffman DM, Crampton L, Sernia C, Nguyen TV & Ho KK. Short-term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. Journal of Clinical Endocrinology and Metabolism 1996 81 1123-1128.